Literature DB >> 16864814

Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics.

A M Abbatecola1, M R Rizzo, M Barbieri, R Grella, A Arciello, M T Laieta, R Acampora, N Passariello, F Cacciapuoti, G Paolisso.   

Abstract

BACKGROUND: Postprandial plasma glucose (PPG) excursion is a significant determinant of overall metabolic control as well as an increased risk for diabetic complications. Older persons with type 2 diabetes mellitus (DM2) are more likely to have moderate cognitive deficits and neurophysiologic and structural changes in brain tissue. Considering that poor metabolic control is considered a deranging factor for tissue/organ damage in diabetics, the authors hypothesized that PPG excursion is associated with a decline in cognitive functioning and that a tighter control of PPG may prevent cognitive decline.
METHODS: Two groups of aged diabetic patients were randomly selected to be treated with repaglinide (n = 77) or glibenclamide (n = 79).
RESULTS: Coefficient of variation of PPG (CV-PPG) was associated with Mini-Mental State Examination (MMSE) scores (r = -0.3410; p < 0.001) and a composite score of executive and attention functioning (r = -0.3744; p < 0.001) after adjusting for multiple confounders. Both groups showed a significant decline in hemoglobin A1c (HbA1c) and fasting plasma glucose (FPG), but only the repaglinide group demonstrated a significant decline of CV-PPG over time. In models investigating the change in cognitive functioning over time, adjusted for HbA1c and CV-FPG, a decline in cognitive functioning was observed only in the glibenclamide group (p < 0.001). After adjusting for CV-PPG, the authors no longer found a decline in executive and attention functioning composite score (p = 0.085) or the MMSE (p = 0.080) with glibenclamide.
CONCLUSIONS: Exaggerated postprandial glucose (PPG) excursions are associated with a derangement of both global, executive, and attention functioning. A tighter control of PPG may prevent cognitive decline in older diabetic individuals.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16864814     DOI: 10.1212/01.wnl.0000224760.22802.e8

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  39 in total

Review 1.  Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia.

Authors:  Almudena Areosa Sastre; Robin Wm Vernooij; Magali González-Colaço Harmand; Gabriel Martínez
Journal:  Cochrane Database Syst Rev       Date:  2017-06-15

2.  The influence of subclinical cardiovascular disease and related risk factors on cognition in type 2 diabetes mellitus: The DHS-Mind study.

Authors:  Christina E Hugenschmidt; Fang-Chi Hsu; Satoru Hayasaka; J Jeffrey Carr; Barry I Freedman; David L Nyenhuis; Jeff D Williamson; Donald W Bowden
Journal:  J Diabetes Complications       Date:  2013-05-07       Impact factor: 2.852

Review 3.  [Geriatric aspects for the management of diabetes mellitus].

Authors:  Joakim Huber; Michael Smeikal; Monika Lechleitner; Peter Fasching
Journal:  Wien Klin Wochenschr       Date:  2016-04       Impact factor: 1.704

Review 4.  Lixisenatide - A New Glucagon-like Peptide 1 Receptor Agonist in the Treatment of Type 2 Diabetes.

Authors:  Josep Vidal
Journal:  Eur Endocrinol       Date:  2013-08-23

Review 5.  Diabetes mellitus and cognitive impairments.

Authors:  Elham Saedi; Mohammad Reza Gheini; Firoozeh Faiz; Mohammad Ali Arami
Journal:  World J Diabetes       Date:  2016-09-15

6.  Adiposity predicts cognitive decline in older persons with diabetes: a 2-year follow-up.

Authors:  Angela Marie Abbatecola; Fabrizia Lattanzio; Liana Spazzafumo; Anna Maria Molinari; Michele Cioffi; Raffaele Canonico; Luigi Dicioccio; Giuseppe Paolisso
Journal:  PLoS One       Date:  2010-04-23       Impact factor: 3.240

Review 7.  Frailty and safety: the example of diabetes.

Authors:  Angela M Abbatecola; Fabiola Olivieri; Andrea Corsonello; Felice Strollo; Alessia Fumagalli; Fabrizia Lattanzio
Journal:  Drug Saf       Date:  2012-01       Impact factor: 5.606

Review 8.  Therapeutic Potential of Antidiabetic Medications in the Treatment of Cognitive Dysfunction and Dementia.

Authors:  Hiroyuki Umegaki
Journal:  Drugs Aging       Date:  2016-06       Impact factor: 3.923

9.  [Geriatric aspects for the management of diabetes mellitus].

Authors:  Joakim Huber; Michael Smeikal; Monika Lechleitner; Peter Fasching
Journal:  Wien Klin Wochenschr       Date:  2012-12       Impact factor: 1.704

10.  International Diabetes Federation guideline for management of postmeal glucose: a review of recommendations.

Authors:  A Ceriello; S Colagiuri
Journal:  Diabet Med       Date:  2008-10       Impact factor: 4.359

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.